Clamart, France – December 3, 2025 – MicroPort® CRM, a pioneering company in the field of Cardiac Rhythm Management, today announced the broader deployment of the SmartView Connect™ App Mobile in Europe and Australia. This expansion follows the app’s CE mark approval under the new Medical Device Regulation (MDR 2017/745) and its initial rollout in selected countries in March 2025.
The SmartView Connect™ App Mobile, designed for Android smartphones, enables remote monitoring on the patient’s smartphone for those implanted with compatible pacemakers, Implantable Cardiac Defibrillators (ICDs), and Cardiac Resynchronization Therapy Defibrillators (CRT-Ds), allowing them to stay seamlessly connected with their Cardiology department. By securely transmitting device data via Bluetooth® to the SmartView™ remote monitoring network, the app removes the need for a bedside monitor, ensuring convenience while maintaining high standards of cybersecurity and data protection.
To support patient autonomy and understanding, the SmartView Connect™ App Mobile includes educational resources such as videos and documents available in four languages: English, French, Italian, and Spanish. These materials help patients better understand how to use the app and manage their connected cardiac care with confidence.
Early adopters, both patients and healthcare professionals, have shared highly positive experiences with the SmartView Connect™ App Mobile. They rated, from a recent survey, the ease of installation: 8.5/10 and the overall satisfaction: 8.7/10.
Patients commented: “I can check every day that everything is going well, which gives me confidence.” “It’s easy for me to check on my phone.” “I can check that everything is going well myself, which is reassuring.” “I feel safer.” “Very simple to use.”
Healthcare professionals praised the app’s smooth installation and ease of use, highlighting its global applicability, enhanced patient safety, and independence from traditional transmitters.
“The full launch of SmartView Connect™ App Mobile in Europe and Australia represents a major step forward in the evolution of connected cardiac care,” said Vincent Leveaux, COO at MicroPort® CRM. “By combining patient education, and real-world usability, we are empowering patients to play an active role in their follow-up while supporting clinicians with reliable, secure, and timely data.”
The SmartView Connect™ App Mobile is now available for download on the Google Play store in participating European and Australian markets.
MicroPort® CRM continues to work on expanding its connectivity solutions and geographic reach to bring the benefits of remote cardiac monitoring to more patients worldwide.
About MicroPort® CRM:
MicroPort® CRM is a pioneering company in the field of Cardiac Rhythm Management (CRM) with global headquarters in Clamart, near Paris, France and an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853). With over 60 years of expertise and innovations, MicroPort® CRM develops, manufactures and commercializes cardiac pacemakers, implantable cardiac defibrillators, cardiac resynchronization systems and ECG diagnostic solutions for the management of cardiac rhythm disorders and heart failure, globally. These state-of-the-art products are manufactured in Clamart, France, Saluggia, Italy, and in Santo Domingo, Dominican Republic. MicroPort® CRM also distributes MicroPort® solutions in Interventional Cardiology and Electrophysiology in Europe.
More information is available at www.microport.com.
Media Contact:
Mrs. Sonia Thareau
Director Corporate Affairs and Communication - MicroPort® CRM
sonia.thareau@crm.microport.com